Story perspectives

Moderna–Merck Personalized mRNA Vaccine Delays Melanoma Recurrence in Phase 3

8/25/2026

Summary

Story summary

Moderna and Merck report their personalized mRNA vaccine delayed melanoma recurrence in a Phase 3 trial.
The INTerpath-001 trial enrolled 1,137 stage IIB-IV melanoma patients whose tumors were surgically removed.
Patients received Keytruda alone or with intismeran autogene, a vaccine targeting up to 34 neoantigens.
The combination improved recurrence-free and distant metastasis-free survival without new safety concerns.
Moderna’s share price jumped 177% on the day the trial results were announced.

1 of 1

Story summary

Moderna and Merck report their personalized mRNA vaccine delayed melanoma recurrence in a Phase 3 trial.
The INTerpath-001 trial enrolled 1,137 stage IIB-IV melanoma patients whose tumors were surgically removed.
Patients received Keytruda alone or with intismeran autogene, a vaccine targeting up to 34 neoantigens.
The combination improved recurrence-free and distant metastasis-free survival without new safety concerns.
Moderna’s share price jumped 177% on the day the trial results were announced.